Trial · NCT00744497
Results by group154
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 154
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Overall Survival: Time From Randomization to Date of Death | Placebo | 21.2 | 95% Confidence Interval 20.0 to 23.4 | Months | |
| Overall Survival: Time From Randomization to Date of Death | Dasatinib | 21.5 | 95% Confidence Interval 20.3 to 22.8 | Months | |
| Percentage of Participants With an Objective Tumor Response by Modified Response Evaluation Criteria in Solid Tumors (RECIST) | Placebo | 31.85 | 95% Confidence Interval 27.21 to 36.78 | Percentage of participants | |
| Percentage of Participants With an Objective Tumor Response by Modified Response Evaluation Criteria in Solid Tumors (RECIST) | Dasatinib | 30.45 | 95% Confidence Interval 25.86 to 35.34 | Percentage of participants | |
| Time to First Skeletal-related Event (SRE) | Placebo | 31.1 | 95% Confidence Interval 28.8 to NA | Months | |
| Time to First Skeletal-related Event (SRE) | Dasatinib | NA | 95% Confidence Interval NA to NA | Months | |
| Percentage of Participants With A Reduction in Urinary N-telopeptide (uNTx) Level From Baseline | Placebo | 60.60 | 95% Confidence Interval 55.14 to 65.86 | Percentage of participants | |
| Percentage of Participants With A Reduction in Urinary N-telopeptide (uNTx) Level From Baseline | Dasatinib | 66.04 | 95% Confidence Interval 60.58 to 71.21 | Percentage of participants | |
| Progression-free Survival (PFS) | Placebo | 11.1 | 95% Confidence Interval 10.8 to 11.7 | Months | |
| Progression-free Survival (PFS) | Dasatinib | 11.8 | 95% Confidence Interval 11.1 to 13.4 | Months | |
| Time to Prostate Specific Antigen (PSA) Progression | Placebo | 6.9 | 95% Confidence Interval 6.5 to 7.4 | Months | |
| Time to Prostate Specific Antigen (PSA) Progression | Dasatinib | 7.2 | 95% Confidence Interval 6.6 to 7.9 | Months | |
| Percentage of Participants With a Reduction in Pain Intensity From Baseline | Placebo | 71.52 | 95% Confidence Interval 67.19 to 75.57 | Percentage of participants | |
| Percentage of Participants With a Reduction in Pain Intensity From Baseline | Dasatinib | 66.59 | 95% Confidence Interval 61.85 to 71.09 | Percentage of participants | |
| Number of Participants With Serious Adverse Event (SAEs), Drug-related SAEs, Drug-related AEs, Drug-related AEs Leading to Discontinuation, and All Deaths | Placebo | All deaths | 505 | Participants | |
| Number of Participants With Serious Adverse Event (SAEs), Drug-related SAEs, Drug-related AEs, Drug-related AEs Leading to Discontinuation, and All Deaths | Dasatinib | All deaths | 506 | Participants | |
| Number of Participants With Serious Adverse Event (SAEs), Drug-related SAEs, Drug-related AEs, Drug-related AEs Leading to Discontinuation, and All Deaths | Placebo | Deaths within 30 days of end of treatment | 50 | Participants | |
| Number of Participants With Serious Adverse Event (SAEs), Drug-related SAEs, Drug-related AEs, Drug-related AEs Leading to Discontinuation, and All Deaths | Dasatinib | Deaths within 30 days of end of treatment | 79 | Participants | |
| Number of Participants With Serious Adverse Event (SAEs), Drug-related SAEs, Drug-related AEs, Drug-related AEs Leading to Discontinuation, and All Deaths | Placebo | All SAEs | 317 | Participants | |
| Number of Participants With Serious Adverse Event (SAEs), Drug-related SAEs, Drug-related AEs, Drug-related AEs Leading to Discontinuation, and All Deaths | Dasatinib | All SAEs | 381 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00744497/results